Menu

Investors

jefferies 2018

The Jefferies Global Healthcare 2018 Presentation can be watched here.

Dune Medical Devices strives to improve the standard of care for cancer patients every single day. With a first indication in breast cancer, our proprietary radiofrequency spectroscopy platform has been utilized in over 10,000 patients. Our first device, MarginProbe®, has been shown to reduce re-excision rates in lumpectomy surgery by 62%.

And we are not stopping there. Our RF platform based biopsy device is currently in development thanks in part to a $3 million EC Horizon 2020 grant.

If you would like to know more about our business and its potential, contact info@dunemedical.com.

01Aug 18

New Research Shows MarginProbe® Reduces Re-Excision Rates for Breast Conserving Surgery by 61%, Giving Renewed Hope to Breast Cancer Patients

A study recently published in the American Journal of Surgery demonstrates that proper use of Dune Medical Devices’ intraoperative margin assessment device, MarginProbe, results in a significant identification of positive margins and a resulting reduction in the re-excision rate for breast conserving surgery - the standard option for patients with early-stage breast cancer.
read more
×
Search